Abstract: The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

Abstract: The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula: (wherein R1, R2, Het, D, E, X, Y, Z, m, n, p, q, r, s and t are as defined herein), methods for their preparation, their use in synthesizing antibody drug conjugates, and the resulting antibody drug conjugates made with components having heteroaryl sulfone-based conjugation handles.

Abstract: The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula: (wherein R1, R2, Het, D, E, X, Y, Z, m, n, p, q, r, s and t are as defined herein), methods for their preparation, their use in synthesizing antibody drig conjugates, and the resulting antibody drig conjugates made with components having heteroaryl sulfone-based conjugation handles.

Abstract: Process for making a conditioning gel phase comprising: i) forming an aqueous dispersion of fatty alcohol and amidoamine; ii) adding a cationic surfactant to the aqueous dispersion and mixing; and iii) neutralizing the amidoamine, wherein the temperature of the mixture of cationic surfactant in the aqueous dispersion is maintained at from 56° C. to 67° C.

Abstract: A scroll screen centrifugal separator includes a distributor that is configured to receive slurry received from a feed conduit. The distributor is configured to deflect the received slurry to a screen of the scroll screen centrifugal separator. In some embodiments, the distributor may include a distributor that has a flat surface encircled by a lip or having one or more lips positioned on the flat surface, an inclined surface, or a declined surface that faces the mouth of the feed conduit. In other embodiments, the distributor may include a plurality of dam members for defining passageways through which slurry is passable through the distributor prior to being ejected to a screen of the separator. In other embodiments, the distributor may include a distributor plate that has a plurality of radial arms attached thereto that are configured to direct slurry to the basket with a rotational velocity.

Abstract: A scroll screen centrifugal separator includes a distributor that is configured to receive slurry received from a feed conduit. The distributor is configured to deflect the received slurry to a screen of the scroll screen centrifugal separator. In some embodiments, the distributor may include a distributor that has a flat surface encircled by a lip or having one or more lips positioned on the flat surface, an inclined surface, or a declined surface that faces the mouth of the feed conduit. In other embodiments, the distributor may include a plurality of dam members for defining passageways through which slurry is passable through the distributor prior to being ejected to a screen of the separator. In other embodiments, the distributor may include a distributor plate that has a plurality of radial arms attached thereto that are configured to direct slurry to the basket with a rotational velocity.

Abstract: Process for making a conditioning gel phase comprising: forming an aqueous isotropic solution of cationic surfactant; mixing the aqueous isotropic solution of cationic surfactant withmoltenfatty alcohol wherein the temperature during mixing the fatty alcohol with the isotropic cationic surfactant solution is maintained from 55° C. to 65° C.

Abstract: Process for making a conditioning gel phase comprising: i) forming an aqueous dispersion of fatty alcohol and amidoamine; ii) adding a cationic surfactant to the aqueous dispersion and mixing; and iii) neutralising the amidoamine, wherein the temperature of the mixture of cationic surfactant in the aqueous dispersion is maintained at from 56° C. to 67° C.

Abstract: Process for making a conditioning gel phase comprising:—forming a ‘comelt’ in a first vessel comprising fatty alcohol and cationic component and 0-15% wt. comelt water—independently adding the ‘comelt’ and water to a mixing vessel—mixing, wherein the temperature of the mixture of the ‘comelt’ and the water is maintained at from 56-65° C., preferably from 58-62° C., more preferably 60° C. when in the mixing vessel, wherein the fatty alcohol comprises from 8 to 22 carbons, wherein the cationic component comprises from 0-70% cationic component, cationic surfactants have the formula N?R1R2R3R4, more preferably from 30-60% wt. cationic surfactant component, and wherein R1, R2, R3 and R4 are independently (C1 to C30) alkyl or benzyl.

Abstract: Conditioning composition comprising from 0.4 to 8% wt. fatty alcohol having from 8-22 carbons, from 0.1 to 2% wt. cationic surfactant component, water, and wherein the composition has a Draw Mass of from 1 to 250g.

Abstract: Process for making a conditioning gel phase comprising:—forming a ‘comelt’ in a first vessel comprising fatty alcohol and cationic component and 0-15% wt. comelt of water (A) adding the ‘comelt’ to a second vessel containing water at 50-60° C. (B)—mixing wherein the temperature of the mixture of the comelt and the water in the second vessel (B) is controlled such that it is maintained from 56-65° C., preferably from 58-62° C., more preferably 60° C., wherein the fatty alcohol has from 8 to 22 carbons and wherein the cationic component comprises from 0-70% wt. cationic component, cationic surfactants have the formula N+R1R2R3R4, more preferably from 30-60% wt. cationic surfactant component, and wherein R1, R2, R3 and R4 are independently (C1 to C30) alkyl or benzyl and process for manufacturing a conditioning composition by forming a conditioning gel phase obtained by any of claims 1-7 and then adding any remaining ingredients.

Abstract: A method and system for generating a test bench for testing a requirement is described. According to an embodiment, a test bench generator subsystem automatically chooses a test template based on a user specification of a requirement to be tested. The requirement is automatically associated with information such as parameters, context identifiers, and success criteria. The subsystem automatically generates a test bench data construct for a simulation that will test the requirement and evaluate success or failure. In an embodiment, generating the test bench includes automatically choosing a system model for the test bench.

Abstract: There is disclosed a method of creating an LDPC code that is defined by a parity-check matrix H. The parity-check matrix H is derived from a (0,1)-geometry which is induced by a finite inversive space. This inversive space has an order q where every circle in the inversive space contains exactly q+1 points, q is preferably even, and most preferably equal to 2. Where the inversive space has a dimension n. Where the (0,1)-geometry is formed as a derived geometric structure based on pencils of degree m?n in the inversive space. The method includes construction of a binary K by N matrix H labelled by K circles and N pencils of the inversive space, wherein the (i, j)-entry of the matrix is 1 if circle i belongs to pencil j, and 0 otherwise. If the degree of the pencil is given by 2 then the parity-check matrix H needs to be transposed, i.e. HT is used instead of H. A method of transmitting a message, a coder, a decoder and a data transmission system using such codes are also disclosed.

Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.

Abstract: During voice-over-Internet-protocol calls, data are gathered about packet loss on the path over the IP network. An algorithm (in the preferred embodiment, the Sliding Window Exponential Average Algorithm) is used to evaluate the packet loss. The Sliding Window Exponential Average Algorithm allows for past performance to be considered along with current performance. If the resulting evaluation fails to meet predetermined criteria, the path over the IP network is blocked and calls are routed over an alternative.

Abstract: Process for the manufacture of an oral composition, said oral composition comprising from 5 to 60% by weight calcium carbonate as abrasive, said method characterised by the preparation of a slurry which comprises substantially all of the ingredients present in said oral composition followed by the addition of a thickening mixture to form said oral composition.

Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

Abstract: Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.

Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.